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Background. Chronotherapy with antineoplastic 
drugs is a rather new strategy of reducing cytotoxic side 
effects. Because the circadian timing of 5-fluorouracil(5- 
FU) was reported to result in a higher efficacy and lower 
toxicity, the authors conducted a chronopharmacologic 
Phase I trial with 5-FU and folinic acid (FA). 
Methods. Eight patients with advanced colorectal 
cancer received 5-FU (initial dose of 500 mg/m2/day) and 
FA (20 mg/mz/day] as a continuous intravenous infusion 
over 5 consecutive days. Using a portable, ambulatory 
drug delivery system, 75% of the daily dose of 5-FU and 
FA were given from 0h00-7h00, and the remaining 25% 
from 7h00-24hOO. Treatment courses were repeated after 
28 days. Dose escalations of 250 mg/mz/day of 5-FU and 
10 mg/m2/day of FA per course were performed in the 
absence of any toxicity greater than WHO (World Health 
Organization) grade 2. 
Results. Dose-limiting toxicity WHO grade 3 was ob- 
served at a dose of 750 mg/mz/day of 5-FU and 30 mg/m’/ 
day of FA in five, and 1000 mg/m2/day of 5-FU and40 mg/ 
m2/day of FA in two patients, respectively. One patient 
tolerated 1000 mg/mz/day of 5-FU and 40 mg/m2/day of 
FA, but the treatment was stopped before further dose es- 
calation because of rapid disease progression. Mucositis 
was the dose-limiting toxicity in seven patients and diar- 
rhea in two. Disease stabilization occurred in three pa- 
tients and disease progression in five. Compared with 
conventional Phase 1/11 trials using a 5-day infusion reg- 
imen, the maximal tolerated dose of 5-FU and FA was 
slightly higher but significantly lower than in a chronoth- 
erapeutic trial that used a different, sinusoidal mode of 
drug application. 
Conclusion. Based on these results, the authors feel 
justified to caution that the circadian timing of 5-FU plus 
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FA may not always allow the safe application of high dose 
levels. Future Phase 1/11 studies need to define whether 
specific drug delivery systems or schedules are necessary 
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Colorectal carcinoma is one of the commonest neopla- 
sias with an annual incidence of about 40 per 100,000 in 
Germany. Early stage patients may be cured by surgery, 
whereas all attempts to improve survival in advanced 
colorectal cancer have been frustrating. 5-fluorouracil 
(5-FU) is still the single most effective drug against co- 
lorectal cancer. Given as prolonged infusion, 5-FU in- 
duces remissions in 19-31% of the patients (mean, 
25%); it is somewhat less potent given as conventional 
intravenous (IV) push (remission rate, 6-14 %; mean, 
lo%).’ So far, combinations of 5-FU with other cyto- 
static drugs have failed to significantly improve these 
results or have resulted in an increased morbidity.’ 
Preclinical studies have shown that the antineo- 
plastic activity of 5-FU can be potentiated by folinic acid 
(FA),2-5 a strategy termed ”biochemical modulation,” 
because these agents enhance the intracellular bio- 
chemical effects and the antineoplastic activity of 5-FU 
in ~ i t r o . ~  Accordingly, early Phase I and I1 trials sug- 
gested that FA might increase the therapeutic activity of 
5-FU in patients with advanced colorectal c a r ~ i n o m a . ~ , ~  
Therefore, several Phase I1 trials with 5-FU plus FA 
have been performed that uniformly reported a higher 
rate of clinical remissions for 5-FU plus FA than for 5- 
FU a l ~ n e . ~ - ~ ~  In some studies, a small, but significant 
2906 CANCER Iune 25, 2994, Volume 73, No. 12 
improvement of the overall survival was reported. 10,12,13 
However, a metaanalysis of nine large randomized clin- 
ical trials revealed that the overall survival of patients 
with advanced colorectal cancer could not be prolonged 
by combining 5-FU with FA.I5 Nevertheless, the bene- 
fits of modulating the effects of 5-FU with FA in terms 
of tumor shrinkage seem to justify further research and 
clinical trials in that dire~tion. '~ 
The efficacy of 5-FU against colorectal cancer is 
characterized by a dose-response relationship." 
Therefore, several strategies have been tested to over- 
come the dose-limiting toxicity of 5-FU or to increase 
the local concentration of the drug at the tumor site. 
These strategies include chemotherapy regimens with 
5-FU "loading" doses, continuous IV infusion ranging 
from 24 hours to 14 or 70 consecutive days, and the 
local drug application by implantable delivery sys- 
The circadian timing of antineoplastic drugs has 
been introduced as a strategy of reducing cytotoxic side 
 effect^.^'-^^ This strategy is based on the principle that 
all functions of the human organism are organized in a 
time-dependent way. For example, the numbers of cir- 
culating leukocytes, lymphocytes, erythrocytes, and 
platelets are not constant, but show considerable diur- 
nal  fluctuation^.^"-^^ Circadian rhythms have also been 
demonstrated for the mitotic activity of the bone mar- 
row, the number of hematopoietic precursors in human 
blood and bone marrow, and the phagocytic activity of 
peripheral blood  granulocyte^.^',^^-^^ It has been re- 
ported both in experimental animal systems and in clin- 
ical trials that the toxic side effects of 5-FU can be de- 
creased by administration of the drug during the rest 
span (i.e., nighttime in human beings).36 Preliminary re- 
sults of a Phase I study in 34 patients with advanced 
colorectal cancer indicated that the circadian modula- 
tion of the drug application allowed the safe delivery of 
a 7.5 g/m2/course of 5-FU (mean dose over 5 consecu- 
tive days) with surprisingly low In that study, 
the delivery rate of 5-FU varied sinusoidally with a peak 
flow rate at 4h00. A dose escalation of lg/m2/course 
was performed in each patient. Side effects such as sto- 
matitis, diarrhea, leukopenia, and anemia WHO grade 
2 were seen in less than 10%. Partial remission was 
achieved in 10 patients, and disease stabilization in 15 
patients.37 In another trial, the circadian modulation of 
the delivery of 5-FU, FA, and oxaliplatin in 93 patients 
with advanced colorectal cancer allowed a relatively 
high dose intensity with low toxicity, thereby achieving 
a response rate of 54% (partial or complete remissi- 
o n ~ ) . ~ *  Although the mechanisms underlying these cir- 
cadian changes of 5-FU cytotoxicity are not fully un- 
derstood, it has been suggested that the metabolic deg- 
radation of 5-FU by hepatic enzymes is regulated in a 
tems, 1.1 7-24 
time-dependent way.39 Accordingly, constant infusions 
with 5-FU do not result in constant 5-FU plasma con- 
centrations but follow a circadian rhythm.40 
The circadian timing of 5-FU in combination with 
FA has not been tested so far. Stimulated by the above- 
mentioned observations of a higher efficacy and lower 
toxicity of 5-FU by an appropriate circadian drug tim- 
ing, we, therefore, asked whether the circadian modu- 
lation of the combination of 5-FU plus FA would 
improve the tolerance and/or efficacy of this drug 
combination. For that purpose, we conducted a chrono- 
pharmacologic Phase I trial in eight patients with ad- 
vanced colorectal cancer who received 75% of the daily 
dose of 5-FU and FA as a continuous IV infusion during 
night hours (from midnight to 7h00) and the remaining 
25% during the rest of the day. The results presented 
suggest that the circadian timing of 5-FU and FA as per- 
formed in this study does not allow the application of 
higher dose levels as compared with constant delivery 
or a bolus regimen. 
Patients and Methods 
Pa tien ts 
Between 1990 and 1992, eight patients (aged 41-71 
years; three women, five men) treated at the outpatient 
clinic of the Department of Hematology and Oncology, 
Medical Clinic, Klinikum Innenstadt, University of Mu- 
nich, Germany, were included in the study. Inclusion 
criteria were the existence of progressive, histologically 
proven, measurable recurrent, or metastatic colorectal 
carcinoma not amenable to surgical resection and caus- 
ing severe symptoms, age under 75 years, a perfor- 
mance status (Karnofsky index) higher than 6O%, and 
an adequate bone marrow function as defined by a leu- 
kocyte count of greater than or equal to 3 X 109/1 and a 
platelet count of greater than or equal to 100 X 109/l. 
Patients with second malignancies were excluded. In- 
formed written consent was obtained from each patient 
according to the Helsinki declaration of human rights. 
The characteristics of these patients are shown in 
Table 1. All patients had undergone surgical resection 
of their primary lesion (four rectal carcinoma and four 
colon carcinoma). Primary staging at diagnosis was per- 
formed according to Dukes.41 Six patients were as- 
signed to Dukes stage C, one to stage A, and one to stage 
D. Six patients had received systemic chemotherapy 
previously, one patient local chemotherapy of liver me- 
tastases, and four patients pelvic radiation. The total 
dose of systemic 5-FU applied before the study ranged 
from 6 to 60 g (Table 1). 
The indications for systemic chemotherapy were 
liver metastases in two patients, local relapses in two 
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Table 1. Study Patients 
Previous chemotherapy Primary lesion 
Total 5-FU Duke's 
Response Site stage Site of relapse 
Patient Age 
no. Sex (yr) Drugs dose (g) 
1 M 41 5 -FU 30 I'D Rectum A Liver 
2 F 65 5-FU 19 PD Sigmoid C Local 
3 M 61 5-FU 14 PD Sigmoid D Local, liver 
4 F 63 5-FU 40 PD Rectum C Local, liver 
5 F 71 5-FU 9 PD Colon C Liver 
6 M 47 5-FU+IFNa 60 I'D Colon C Lung, liver 
7 M 48 None - PD Rectum C Liver, inguinal lymph nodes 
8 M 52 None - PD Rectum C Local 
5-FU + IFNn 
5-FU: 5-fluorouracil; I'D: progressive disease; IFNa: interferon-a. 
patients, the combination of local relapse and liver me- 
tastasis in another two patients, lung metastasis in one 
patient, and a combination of metastases in liver and 
inguinal lymph nodes in another patient. All eight pa- 
tients were evaluable for response and toxicity, whereas 
the evaluation of survival was possible in seven patients 
only, because one patient was lost to follow-up. 
Eligible patients underwent a complete workup in- 
cluding complete history and physical examination. 
Weight and height, complete blood cell count, serum 
bilirubin, creatinine, urea, electrolytes, calcium, total 
proteins, alkaline phosphatase, serum liver transami- 
nases, gamma-glutamyltransferase, lactate dehydroge- 
nase, carcinoembryonic antigen, and CA 19-9 were de- 
termined. Initial radiologic examination examinations 
included chest radiography, computed tomography of 
the abdomen, and abdominopelvic ultrasonography. 
Colonoscopy was done routinely before treatment on- 
set. Clinical examination and all biologic determina- 
tions were done before each therapy course, and radio- 
logic examinations after the second, fifth, and eighth 
treatment course. 
Study Design and Chemotherapeutic Regimen 
All patients received a central venous access port (Port- 
a-Cath, Pharmacia, Freiburg, Germany) to permit am- 
bulatory IV infusion of cytostatic treatment. One ther- 
apy course consisted of five days. All treatment courses 
started with a loading dose of 200 mg of FA (Leuco- 
vorin, Lederle Arzneimittel, Wolfratshausen, Germany) 
given as IV bolus on Day 1, followed immediately by 
continuous, time-modified IV infusion of 5-FU (Fluro- 
blastin, Farmitalia Carlo Erba, Frieburg, Germany) and 
FA delivered by a one-channel, programmable pump 
(Chronomat, Fresenius, Germany). For this treatment, 
5-FU and FA were mixed in the reservoir of the pump 
for a maximum of 48 hours. Previous investigations had 
proven the stability of both drugs for more than 72 
hours when combined in one solution (Dr R. Schenk, 
Lederle, Wolfratshausen, Germany, personal commu- 
nication, 1989). The pump was programmed to infuse 
75% of the total daily dose between OhOO and 7h00, 
and the remaining 25% between 7h00 and 24h00 (Fig. 
1). The first treatment course was always started at a 
I 2 O  1 
............ ,
20 - 
........ ....... ............ - 25% - 
0 4 a 12 16 20 24 
0 1 . . -;-
local time (h) 
Figure 1. Drug delivery schedule as automatically administered for 5 
consecutive days to outpatients with the use of a one-channel 
programmable ambulatory pump (Chronomat, Fresenius, Germany). 
In this example, 1000 mg of 5-fluorouracil(5-FU) and 40 mg of 
folinic acid (FA) were given every 24 hours. Seventy-five percent of 
this dose was applied between OhOO and 7h00, and 25% between 
7h00 and 24h00. Therefore, the pump was programmed to deliver 5- 
FU at infusion rates of 107 mg/hour between OhOO and 7h00, and 
15 mg/hour between 7h00 and 24h00. FA was delivered a t  4.3 mg/ 
hour between OhOO and 7h00, and 0.6 mg/hour between 7h00 and 
24h00. In addition to the daily dose of FA, a single-loading dose of 
200 mg of FA was given as IV bolus on Day 1, before beginning the 
infusion (not shown). 
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dose of 500 mg/m2/day of 5-FU for 5 days and 20 mg/ 
m2/day of FA for 5 days. The initial dose level was cho- 
sen under the influence of a report by LGvi and cowork- 
ers who did observe little WHO grade 3 or 4 toxicity 
at  comparable doses.3s In absence of any toxicity WHO 
grade 3 or 4, the dose of 5-FU was increased by 250 mg/ 
m2/day and the dose of FA by 10 mg/m2/day in the 
following treatment course, respectively. The maximal 
dose planned in the study protocol was 1500 mg/m2/ 
day of 5-FU and 60 mg/m2/day of FA (in the absence 
of any toxicity greater than WHO grade 2). In case of 
dose-limiting toxicity, the treatment with 5-FU and FA 
was reduced to the dose level of the previous treatment 
course and continued until disease progression oc- 
curred. The maximal tolerated dose was defined as a 
dose without side effects greater than WHO grade 2. 
The following criteria were established for treat- 
ment discontinuation: tumor progression by more than 
25% after two treatment courses, appearance of new 
metastatic lesions, toxicity WHO grade 4 even after 
dose reduction, manifestation of secondary malignan- 
cies, and refusal of the patient to continue the treat- 
ment. 
The following endpoints were evaluated: maximal 
tolerated dose of 5-FU and FA (i.e., toxicity less than 
WHO grade 3); side effects of cytotoxic drugs according 
to WHO criteria; clinical response and duration of clini- 
cal remission using Union Internationale Contre le Can- 
cer criteria; and survival. Regular follow-up examina- 
tions were performed in all patients after discontinuing 
study treatment. 
Results 
Circadian Timing of 5-FU and Folinic Acid Does Not  
Reduce the Cytotoxic Side Eflects 
The number of treatment courses applied, and the max- 
imal tolerated dose of 5-FU and FA are shown in Table 
2. One patient received nine, two patients six, three pa- 
tients three, and two patients two complete treatment 
courses with 5-FU and FA. At the initial dose of 500 
mg/m2/day of 5-FU and 20 mg/m2/day of FA, this 
treatment could be given to all patients without major 
toxicity. However, dose escalation had to be stopped 
due to dose-limiting toxicity in the majority of patients 
(seven out of eight; Table 2). Dose-limiting side effects 
(WHO grade 3) occurred at 750 mg/m2/day of 5-FU 
and 30 mg/m2/day of FA in five patients and at 1000 
mg/m2/day of 5-FU and 40 mg/m2/day of FA in two 
patients. Only in one patient (Patient 2), 1000 mg/m2/ 
day of 5-FU and 40 mg/m2/d of FA were tolerated with 
acceptable toxicity (burning-hand-and-feet syndrome, 
WHO grade 2), but further dose escalations were not 
possible because disease progression occurred at the site 
of relapse, which required a surgical resection of the sig- 
moidal tumor mass. Thus, the maximal tolerated dose 
of 5-FU and FA was 2500 mg/m2/course and 300 mg/ 
m2/course, respectively, in five patients, 3750 mg/m2/ 
course and 350 mg/m2/course, respectively, in two pa- 
tients, and greater than or equal to 5000 mg/m2/course 
and 400 mg/m2/course, respectively, in one patient 
(median of 5-FU, 2500 mg/m2/course and of FA 300 
mg/m2/course) (Table 2). 
Mucositis was the most frequent and severe side 
effect. Seven out of eight patients had mucositis WHO 
grade 3 (Table 3), which was, therefore, the major dose- 
limiting factor according to the definitions in the study 
protocol. In one of these patients, the mucositis affected 
the colostomy. In two patients, severe diarrhea (WHO 
grade 3) was also observed. Nausea (WHO grade 2) oc- 
curred in one patient that could be controlled by the oral 
administration of a single dose of 10 mg of metoclo- 
pramide. Mild skin problems (WHO grade 1-2) oc- 
curred in three patients, two of which were burning- 
hand-and-feet syndromes. No severe side effects 
(greater than WHO grade 1) on the central or peripheral 
neural system or on the hematopoietic system were 
seen. 
Because severe side effects (mucositis and diarrhea, 
WHO grade 3) were seen in the majority of patients at 
dose levels only slightly higher or similar as compared 
with conventional Phase 1/11 studies using 5-day infu- 
sions of 5-FU and FA at a constant rate,42 this study was 
closed after including eight patients. 
Response to  Treatment and Survival 
In five patients, the time-modified chemotherapy with 
5-FU and FA proved to be inactive and had to be dis- 
continued because of disease progression under treat- 
ment (Patients 2, 5, 6,  7, and 8). These patients were 
referred to a third-line chemotherapy (Patients 6,8), or 
to a surgical resection of the local tumor mass at the 
relapse site (Patient 2), or were stopped from chemo- 
therapeutic treatment because of proven inefficacy (Pa- 
tients 5 and 7). In all these patients, treatment was dis- 
continued very early, i.e., after two or three treatment 
courses (Patients 2, 5, 6, 7, and 8). With one exception 
(Patient 2), all these patients received 5-FU and FA at 
the maximal tolerated dose (Patients 5, 6, 7, and 8). In 
the three remaining patients, chemotherapy with 5-FU 
and FA at the maximal tolerated dose induced an in- 
termittent disease stabilization that lasted 4 months 
(i.e., four treatment courses) in two patients (Patients 3 
and 4) and 8 months (i.e., eight treatment courses) in 
one patient (Patient 1). No partial or complete remission 
was seen. 
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Table 2. Maximal Tolerated Dose of 5-FU and FA, Response to Treatment, and Survival 
Patient 
no. 
Survival 
Treatment Highest dose Highest dose Dose-limiting Response since 
courses tolerated tolerated* toxicity and beginning 
given (5-FU/m2/5 days) (FA/m’/5 days) (WHO Grade 3) duration (mo) 
1 9 2500 mg 300 mg Mucositis SD for 8 mo 12 
3 6 3750 mg 350 mg Mucositis SD for 4 mo 9 
2 3 5000 mg 400 mg Nonet PD 1 7 t  
4 6 3750 mg 
5 2 2500 mg 
6 3 2500 rng 
7 3 2500 mg 
350 mg Muc. + diarrh. SD for 4 mo 12 
300 mg Muc. + diarrh. I’D 12+ 
300 mg Mucositis PD 6 
300 mg Mucositis I’D Not known 
8 2 2500 mg 300mg Mucositis PD 7+ 
5-FU: 5-fluorouracil; FA: folinic acid; WHO: World Health Organization; muc. + diarrh.: mucositis and diarrhea; I’D: progressive disease; SD: stable disease. 
* Includes 200 mg FA bolus i.v. on day 1 (loading dose). 
t In patient 2, dose escalation was stopped before achieving dose-limiting toxicity, because disease progression occurred under treatment. 
Note: The maximal tolerated dose was defined as dose at which no side effects > WHO Grade 2 were seen (see Methods section). 
Four patients died within 12 months after the treat- 
ment was stopped. One patient did not return to the 
hospital and, therefore, was lost to further follow-up 
examinations. Three patients were still alive 7-17 
months after completing the study treatment. 
Discussion 
Chronotherapy with antineoplastic drugs is a relatively 
new strategy to reduce cytotoxic side effects and/or to 
increase antineoplastic activity of cytostatic 
This approach is derived from experimental evidence 
that both toxic side effects and therapeutic efficacy of 
drugs may vary in a time-dependent With regard 
to the use of cytostatic drugs and cytokines, it has been 
shown that parameters such as DNA synthesis in 
different tissues including intestinal mucosa, skin, bone 
marrow, spleen, testis and function 
and number of different lymphocyte subsets or granu- 
locytes in peripheral blood,31, 46 or numbers of granulo- 
Table 3. Dose-limiting Toxicity 
Toxicity grade (WHO) 
Effect 
Toxicity 1 2 3 4 on dose 
Mucositis 1 0 7$ 0 Limiting 
Diarrhea 0 0 2 0 Limiting 
Nausea 0 1 0 0 None 
Skin 1 :li 2 t  0 0 None 
Blood 0 0 0 0 None 
Neurologic 1 0 0 0 None 
WHO. World Health Organization 
*Rash. 
t Burning hand and feet syndrome. 
t Mucositis affectine the colostoma in one patient. 
cyte-macrophage colony-forming units derived from 
the bone marrow35 show significant circadian variations 
in rodents and human beings. This has led to the devel- 
opment of time-modulated therapeutic regimens for cy- 
tostatic drugs. Circadian timing of the pyrimidine ana- 
log 5-FU with peak flow rates at 4h00 has resulted in 
particularly promising results allowing the application 
of high concentrations of the drug with surprisingly low 
toxicity .37 
Because the combination of 5-FU with FA has a 
higher antitumor efficacy in vitro and in vivo than 5-FU 
alone, we sought to apply the principle of chronother- 
apy to that combination. Eight patients with advanced 
colorectal carcinoma received a time-modulated che- 
motherapy with 5-FU and FA over 5 days in which 75% 
of the total daily dose was given between Oh00 and 
7h00 (Fig. 1). Dose escalations in steps of 250 mg/m’/ 
day per course of 5-FU and 10 mg/m2/day per course 
of FA were performed in the absence of any toxicity 
greater than WHO grade 2 .  In the majority of patients, 
dose escalation was stopped because of dose-limiting 
toxicities (WHO grade 3). These dose-limiting side 
effects were observed at 750 mg/m’/day of 5-FU and 
30 mg/m2/day of FA in five patients, and at 1000 mg/ 
m2/day of 5-FU and 40 mg/m’/day of FA in two pa- 
tients (Table 2). One patient tolerated 1000 mg/m2/day 
of 5-FU and 40 mg/m2/day of FA, but disease progres- 
sion under chemotherapy prevented further dose esca- 
lation. Mucositis was the dose-limiting toxicity in the 
majority of the patients (Table 3). Disease stabilization 
occurred in three patients and disease progression in the 
remaining five patients. Because it became evident that 
5-FU and FA caused major side effects at dose levels of 
greater than or equal to 750 mg/m’/day (23750 mg/ 
m’/course) and greater than or equal to 30 mg/m2/day 
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(2350 mg/m2/course, including a single 200-mg load- 
ing dose) respectively, without impressive beneficial 
effects on the clinical response, this chronopharmaco- 
logic Phase I trial was stopped after including eight pa- 
tients. 
Previous Phase I and I1 studies with the combina- 
tion of 5-FU and FA given as continuous IV infusion 
showed that 5-FU could be given at doses up to 4800 
mg/m2/course in combination with different doses of 
FA (500-3000 mg/m2/course) with acceptable toxic- 
However, considerable side effects were usually 
observed at 5-FU dose levels higher than 2500 mg/m2/ 
course. Most large randomized trials comparing 5-FU 
versus 5-FU plus FA used 5-day IV bolus schedules for 
both drugs." In these Phase 111 trials, the total dose 
ranged from 1850 to 2000 mg/m2/course of 5-FU (370- 
400 mg/m2/day) and from 100 to 1000 mg/m2/course 
of FA (20-200 mg/m2/day ).I5 In comparison, the max- 
imal tolerated dose of 5-FU (median, 2500 mg/m2/ 
course) and FA (median, 300 mg/m2/course) achieved 
with a circadian-modified treatment in this Phase I 
study seemed to be slightly higher. However, this mod- 
est benefit may be the consequence of the infusional 
application of 5-FU rather than of the chronotherapeu- 
tic treatment schedule. 
In comparison with earlier chronopharmacologic 
studies that tried to reduce the cytotoxic side effects by 
circadian timing of 5-FU alone or 5-FU plus the 
benefit achieved with our 5-day continuous IV, chrono- 
pharmacologic treatment regimen was considerably 
smaller. This difference may be explained by schedule- 
dependent interactions of 5-FU and FA. This drug com- 
bination seems to be more toxic when given as a simul- 
taneous, prolonged IV infusion. For example, a weekly 
IV bolus of FA does not reduce the tolerated dose of 
protracted infusional 5-FU4' or of weekly 24-hour infu- 
sions of 5-FU (at 2600 mg/m2/week).48 However, 
when FA is given as continuous IV infusion and simul- 
taneously with 5-FU, as little as 5 mg/m2/day may sig- 
nificantly lower the tolerated dose of 5-FU.49 Similarly, 
frequent oral administration of low-dose FA (9.8 hours) 
seems to increase the toxicity of protracted 5-FU infu- 
s i o n ~ . ~ "  
These observations may explain why our results 
appear somewhat contradictory to a recent report by 
Livi and coworkers who treated 93 patients with ad- 
vanced colorectal carcinoma with a time-modulated 
chemotherapeutic regimen. Their treatment consisted 
of a 5-day continuous infusion of 5-FU (700 mg/m2/ 
day), FA (300 mg/m2/day), and the platinum analogue, 
oxaliplatin (25 mg/m2/day). Using a multichannel am- 
bulatory programmable pump (Intelliject, Aguettant, 
Lyon, France), the infusion rate was modulated sinusoi- 
dally, with peak flow rates at 4h00 for 5-FU and FA and 
at 16h00 for oxaliplatin. Dose escalations were per- 
formed for 5-FU and oxaliplatin, if the toxicity was less 
than WHO grade 2. Despite adding oxaliplatin and giv- 
ing more FA, only little toxicity was observed (110O/o 
WHO grade 2 toxicity for a total of 784 chemotherapy 
courses). Median doses were 3500 mg/m2/course for 5- 
FU, 1500 mg/m2/course for FA, and 125 mg/m2/ 
course for ~xaliplatin.~' The median dose of 5-FU and 
FA achieved in that study was higher than the maximal 
tolerated dose in this study. One cannot exclude the 
possibility that the application of 5-FU and FA in a si- 
nus-wave 38 may be beneficial because this 
mode of application results in a more bolus-like appli- 
cation of 5-FU and FA (around the optimal peak at 
4h00) than a 7-hour flat infusion from Oh00 to 7h00 as 
used in this study. This hypothesis is supported by the 
above-mentioned observations that continuous FA in- 
fusions seem to increase the toxicity of 5-FU and FA 
treatment s c h e d ~ l e s , ~ ~ - ~ "  but it awaits verification by 
further studies with similar dosing schedules. Because 
the pump used by Livi and coworkers was not available 
to us at that time, we had to use a different device that 
allowed only a few, simple changes of the infusion rate 
over a 24-hour period (Fig. 1 and Methods). Therefore, 
we had to choose an approximate imitation rather than 
an exact reproduction of the delivery protocol pub- 
lished previously by the French 
Based on results reported here, we feel justified to 
caution that the circadian timing of 5-FU plus FA may 
not always allow the safe application of high doses in 
patients with advanced colorectal carcinoma. Future 
Phase 1/11 studies will have to define which drug deliv- 
ery systems or schedules are required for an optimized 
chronotherapy with 5-FU and FA. 
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